Skip to main content

Disc Medicine Inc(IRON-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low58.89
Day High62.96
Open:59.17
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Disc Medicine Inc

Select a category then submit the form to load news
Newsfile
Securities Investigation: Levi & Korsinsky Investigates Disc Medicine, Inc. (IRON) on Behalf of Investors
Tipranks
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Butterfly Network (BFLY) and Disc Medicine (IRON)
Tipranks
Wedbush Sticks to Its Buy Rating for Disc Medicine (IRON)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Nyxoah (NYXH), Moderna (MRNA)
Motley Fool
Disc Medicine CFO Sells $720k Worth of Shares Amid FDA Rejection
Tipranks
Disc Medicine Implements Restructuring Following FDA Response
Tipranks
Truist Financial Keeps Their Buy Rating on Disc Medicine (IRON)
Tipranks
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Nautilus Biotechnolgy (NAUT)
Tipranks
Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients
GlobeNewswire
Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Motley Fool
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction
Motley Fool
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
Motley Fool
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
Motley Fool
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst
GlobeNewswire
Disc Medicine to Participate in Upcoming Investor Conferences
Tipranks
Disc Medicine (IRON) Receives a Buy from LifeSci Capital
Tipranks
Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Cochlear (OtherCHEOF) and Disc Medicine (IRON)
Tipranks
Disc Medicine (IRON) Receives a Buy from Cantor Fitzgerald
Tipranks
Disc Medicine Addresses FDA Rejection of Bitopertin Filing
Tipranks
Stifel Nicolaus Sticks to Its Buy Rating for Disc Medicine (IRON)
Tipranks
Analysts Conflicted on These Healthcare Names: Idexx Laboratories (IDXX), Arrowhead Pharmaceuticals (ARWR) and Disc Medicine (IRON)
Tipranks
Analysts Offer Insights on Healthcare Companies: Niagen Bioscience (NAGE) and Disc Medicine (IRON)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON)
Tipranks
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Benitec Biopharma (BNTC)
Tipranks
Disc Medicine Receives FDA Complete Response on Bitopertin
GlobeNewswire
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
Tipranks
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW) and Disc Medicine (IRON)
Tipranks
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Disc Medicine (IRON)
Tipranks
Analysts’ Top Healthcare Picks: Disc Medicine (IRON), Boston Scientific (BSX)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Analysts’ Top Healthcare Picks: Disc Medicine (IRON), Agenus (AGEN)
Tipranks
Analysts Offer Insights on Healthcare Companies: Penumbra (PEN) and Disc Medicine (IRON)

Profile

Disc Medicine Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel treatments for patients suffering from serious hematologic diseases. Disc Medicine Inc., formerly known as Gemini Therapeutics Inc., is based in WAYLAND, Mass.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.